HRP20171515T1 - Spojevi fenoksietilpiperidina - Google Patents

Spojevi fenoksietilpiperidina Download PDF

Info

Publication number
HRP20171515T1
HRP20171515T1 HRP20171515TT HRP20171515T HRP20171515T1 HR P20171515 T1 HRP20171515 T1 HR P20171515T1 HR P20171515T T HRP20171515T T HR P20171515TT HR P20171515 T HRP20171515 T HR P20171515T HR P20171515 T1 HRP20171515 T1 HR P20171515T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
image
intended
Prior art date
Application number
HRP20171515TT
Other languages
English (en)
Croatian (hr)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20171515T1 publication Critical patent/HRP20171515T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171515TT 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina HRP20171515T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
EP13734248.1A EP2867207B1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
HRP20171515T1 true HRP20171515T1 (hr) 2017-11-17

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171515TT HRP20171515T1 (hr) 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina

Country Status (42)

Country Link
US (2) US8962659B2 (enExample)
EP (1) EP2867207B1 (enExample)
JP (1) JP6127136B2 (enExample)
KR (1) KR101653476B1 (enExample)
CN (1) CN104411684B (enExample)
AP (1) AP2014008164A0 (enExample)
AR (1) AR091429A1 (enExample)
AU (1) AU2013280875B2 (enExample)
BR (1) BR112014031616B1 (enExample)
CA (1) CA2875569C (enExample)
CL (1) CL2014003535A1 (enExample)
CO (1) CO7151507A2 (enExample)
CR (1) CR20140553A (enExample)
CY (1) CY1119425T1 (enExample)
DK (1) DK2867207T3 (enExample)
DO (1) DOP2014000287A (enExample)
EA (1) EA024392B1 (enExample)
EC (1) ECSP14033267A (enExample)
ES (1) ES2644812T3 (enExample)
GT (1) GT201400288A (enExample)
HR (1) HRP20171515T1 (enExample)
HU (1) HUE034425T2 (enExample)
IL (1) IL236219A (enExample)
JO (1) JO3296B1 (enExample)
LT (1) LT2867207T (enExample)
MA (1) MA37686B1 (enExample)
ME (1) ME02840B (enExample)
MX (1) MX345324B (enExample)
MY (1) MY173878A (enExample)
NZ (1) NZ701933A (enExample)
PE (1) PE20150182A1 (enExample)
PH (1) PH12015500009B1 (enExample)
PL (1) PL2867207T3 (enExample)
PT (1) PT2867207T (enExample)
RS (1) RS56452B1 (enExample)
SG (1) SG11201408641UA (enExample)
SI (1) SI2867207T1 (enExample)
TN (1) TN2014000501A1 (enExample)
TW (1) TWI599561B (enExample)
UA (1) UA114325C2 (enExample)
WO (1) WO2014004229A1 (enExample)
ZA (1) ZA201408632B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
AU2014366361B2 (en) 2013-12-17 2017-04-20 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
ES2893452T3 (es) 2017-05-18 2022-02-09 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de PGE2
ES2887041T3 (es) 2017-05-18 2021-12-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de PGE2
DK3625224T3 (da) 2017-05-18 2021-11-08 Idorsia Pharmaceuticals Ltd N-substituerede indolderivater
EP3889134B1 (en) * 2019-01-22 2024-09-25 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
MXPA04005555A (es) * 2002-03-18 2005-05-16 Pfizer Prod Inc Procedimientos de tratamiento con agonistas selectivos del receptor ep4.
PL378342A1 (pl) * 2003-01-10 2006-03-20 F. Hoffmann-La Roche Ag Pochodne 2-piperydonu jako agoniści prostaglandyn
KR100747401B1 (ko) 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 e2 길항제로서의 페닐 또는 피리딜 아미드 화합물
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
WO2005105733A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
WO2005105732A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
JP5183628B2 (ja) 2006-06-12 2013-04-17 メルク カナダ インコーポレイテッド Ep4受容体リガンドとしてのインドリンアミド誘導体
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
BRPI0912778B1 (pt) 2008-05-14 2019-04-30 Astellas Pharma Inc. Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
CN107693518A (zh) 2010-02-22 2018-02-16 株式会社AskAt Ep‑4受体拮抗剂在治疗il‑23介导疾病中的用途
CN103097358B (zh) * 2010-09-21 2015-04-08 卫材R&D管理有限公司 药物组合物
KR101760164B1 (ko) * 2011-07-04 2017-07-20 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서 사이클릭 아민 유도체
WO2013004291A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor agonists
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
PH12015500009A1 (en) 2015-03-02
UA114325C2 (uk) 2017-05-25
HK1203937A1 (en) 2015-11-06
EP2867207B1 (en) 2017-08-09
MA37686B1 (fr) 2017-04-28
KR101653476B1 (ko) 2016-09-01
WO2014004229A1 (en) 2014-01-03
TW201412717A (zh) 2014-04-01
TWI599561B (zh) 2017-09-21
NZ701933A (en) 2017-01-27
SG11201408641UA (en) 2015-01-29
ES2644812T3 (es) 2017-11-30
GT201400288A (es) 2015-08-27
US20140005226A1 (en) 2014-01-02
PE20150182A1 (es) 2015-02-13
IL236219A0 (en) 2015-02-01
US20150126555A1 (en) 2015-05-07
MA37686A1 (fr) 2016-09-30
RS56452B1 (sr) 2018-01-31
IL236219A (en) 2017-12-31
CR20140553A (es) 2015-02-04
HUE034425T2 (en) 2018-02-28
CO7151507A2 (es) 2014-12-29
US8962659B2 (en) 2015-02-24
ME02840B (me) 2018-01-20
EA024392B1 (ru) 2016-09-30
MX345324B (es) 2017-01-25
TN2014000501A1 (en) 2016-03-30
US9402838B2 (en) 2016-08-02
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
DOP2014000287A (es) 2015-01-31
JP6127136B2 (ja) 2017-05-10
MY173878A (en) 2020-02-26
CL2014003535A1 (es) 2015-05-08
KR20150013893A (ko) 2015-02-05
AU2013280875A1 (en) 2014-12-04
ZA201408632B (en) 2017-06-28
PL2867207T3 (pl) 2018-01-31
AP2014008164A0 (en) 2014-12-31
PT2867207T (pt) 2017-11-01
AU2013280875B2 (en) 2015-09-24
CA2875569A1 (en) 2014-01-03
BR112014031616B1 (pt) 2022-06-21
SI2867207T1 (sl) 2017-10-30
EA201492255A1 (ru) 2015-03-31
JO3296B1 (ar) 2018-09-16
DK2867207T3 (en) 2017-09-11
PH12015500009B1 (en) 2020-10-09
CN104411684B (zh) 2016-08-24
EP2867207A1 (en) 2015-05-06
AR091429A1 (es) 2015-02-04
LT2867207T (lt) 2017-10-10
JP2015522018A (ja) 2015-08-03
CA2875569C (en) 2016-04-19
CY1119425T1 (el) 2018-03-07
MX2014015953A (es) 2015-07-17
BR112014031616A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
ME02910B (me) Spojevi tetrahidropirolotiazina
ME02896B (me) Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
HRP20171512T1 (hr) Derivati betulina
HRP20161103T1 (hr) Kemijski spojevi
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
HRP20161379T1 (hr) Inhibitori hepatitis c virusa
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
MY174188A (en) Heterocyclyl compounds
HRP20120830T1 (hr) Imidazolkarboksamidi
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
HRP20151000T1 (hr) Antivirusni spojevi
HRP20180237T4 (hr) Metode za liječenje hcv-a
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
EA201491321A1 (ru) Фторметил-5,6-дигидро-4н-[1,3]оксазины
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A